Krystal Biotech (FRA:4KB) Interest Expense: €0.0 Mil (TTM As of Mar. 2026)


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €322.80
GF Value €272.20
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech Interest Expense?

Krystal Biotech FRA:4KB -2.27% 58 Interest Expense is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €272.20 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Krystal Biotech's interest expense for the three months ended in Mar. 2026 was € 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Krystal Biotech's Operating Income for the three months ended in Mar. 2026 was € 46.4 Mil. Krystal Biotech's Interest Expense for the three months ended in Mar. 2026 was € 0.0 Mil. GuruFocus does not calculate Krystal Biotech's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Krystal Biotech  (FRA:4KB) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Krystal Biotech's Interest Expense for the three months ended in Mar. 2026 was €0.0 Mil. Its Operating Income for the three months ended in Mar. 2026 was €46.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €6.3 Mil.

Krystal Biotech's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Krystal Biotech's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Krystal Biotech Inc has enough cash to cover all of its debt. Its financial situation is stable.

Krystal Biotech Interest Expense Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Interest Expense Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.32 0.00 0.00 0.00 0.00

Krystal Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €0.0 Mil mean?
Krystal Biotech (FRA:4KB) has a Interest Expense of €0.0 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Krystal Biotech and its competitors.
Is Krystal Biotech's Interest Expense too high?
Krystal Biotech's current Interest Expense is €0.0 Mil. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Interest Expense compare to TECH and SMMT?
Krystal Biotech's Interest Expense of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current Interest Expense is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €272.20, compared to a current price of €322.80 — trading 18.6% above its estimated fair value. The current Interest Expense is €0.0 Mil. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Interest Expense is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €322.80 is trading 18.6% above its estimated GF Value™ of €272.20. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • Interest Expense: €0.0 Mil
  • GF Value™: €272.20 vs. price of €322.80 (18.6% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€322.80
Price
€272.20
GF Value